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Original article
The ATHENA COVID-19 Study: Cohort profile and first findings for 
people diagnosed with COVID-19 in Queensland, 1 January to 31 
December 2020
Jennifer Welsh, Rosemary J Korda, Ellie Paige, Mark A Morgan, Hsei-Di Law, Tony Stanton, Zoltan MJ Bourne, M Ximena Tolosa, 
Kim Greaves, for the ATHENA (Australians Together Health Initiative) COVID-19 Project Team
Abstract
Background
To date, there are limited Australian data on characteristics of people diagnosed with COVID-19 
and on how these characteristics relate to outcomes. The ATHENA COVID-19 Study was estab-
lished to describe health outcomes and investigate predictors of outcomes for all people diagnosed 
with COVID-19 in Queensland by linking COVID-19 notification, hospital, general practice and 
death registry data. This paper reports on the establishment and first findings for the ATHENA 
COVID-19 Study.
Methods
Part 1 of the ATHENA COVID-19 Study used Notifiable Conditions System data from 1 January 
2020 to 31 December 2020, linked to: Emergency Department Collection data for the same period; 
Queensland Health Admitted Patient Data Collections (from 1 January 2010 to 30 January 2021); and 
Deaths Registrations data (from 1 January 2020 to 17 January 2021).
Results
To 31 December 2020, a total of 1,254 people had been diagnosed with SARS-CoV-2 infection in 
Queensland: half were female (49.8%); two-thirds (67.7%) were aged 20–59 years; and there was an 
over-representation of people living in less-disadvantaged areas. More than half of people diagnosed 
(57.6%) presented to an emergency department (ED); 21.2% were admitted to hospital as an inpa-
tient (median length of stay 11 days); 1.4% were admitted to an intensive care unit (82.4% of these 
required ventilation); and there were six deaths. Analysis of factors associated with these outcomes 
was limited due to small case numbers: people living in less-disadvantaged areas had a lower risk of 
being admitted to hospital (test for trend, p < 0.001), while those living in more remote areas were 
less likely than people living in major cities to present to an ED (test for trend: p=0.007), which 
may reflect differential health care access rather than health outcomes per se. Increasing age (test 
for trend, p < 0.001) and being a current/recent smoker (age-sex-adjusted relative risk: 1.61; 95% 
confidence interval: 1.00, 2.61) were associated with a higher risk of being admitted to hospital.
Conclusion
Despite uncertainty in our estimates due to small numbers, our findings are consistent with what is known 
about COVID-19. Our findings reinforce the value of linking multiple data sources to enhance reporting 
of outcomes for people diagnosed with COVID-19 and provide a platform for longer term follow-up.
Keywords: COVID-19, epidemiology, outcomes, predictors, record linkage, surveillance, morbidity
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Background
The novel coronavirus disease, named 
COVID-19 on 11 February 2020, is caused by 
the SARS-CoV-2 virus. It was first reported 
to the WHO Country Office in China on 31 
December 2019. The outbreak was declared 
a Public Health Emergency of International 
Concern on 30 January 2020. As of 29 June 2021, 
there were over 181 million confirmed cases 
worldwide, with 2.9 million deaths.1 Australia, 
partly due to successful contact tracing and 
isolation protocols, at the same time point had 
only 30,528 confirmed cases and 910 deaths, 
and in Queensland 1,686 confirmed cases and 
seven deaths.2
International data on outcomes among peo-
ple who test positive for SARS-CoV-2, and on 
predictors of outcomes, have been reported 
throughout the pandemic.3 However, outcomes 
are likely to vary with context, including 
population profile, extensiveness of surveillance 
and testing and health system characteristics. 
Furthermore, there has been much less data 
available on characteristics and outcomes for 
people diagnosed with COVID-19 in Australia. 
One study of 204 patients admitted to intensive 
care units in Australia between 27 February 
and 30 June 2020 found that 69% were men 
and 64% had comorbidities (mostly obesity, 
diabetes and chronic cardiac disease).4 People 
with chronic cardiac disease, compared to those 
without, were 3.4 times more likely to die in an 
intensive care unit (ICU). Another more recent 
study focussed on hospitalisation rates in cases 
of COVID-19 diagnosed in New South Wales 
between 1 January and 31 May 2020. However, 
with the exception of age and gender, no other 
health characteristics were reported or linked to 
outcomes.5
It is essential that Australian- and state-specific 
surveillance systems monitor health outcomes 
and health service use as the pandemic pro-
gresses. This paper describes the establishment 
and first findings from the Australians Together 
Health Initiative (ATHENA) COVID-19 Study, 
which was set up to enable ongoing investiga-
tion of health outcomes including service use, 
and predictors of outcomes, for all people diag-
nosed with COVID-19 in Queensland. It does 
so by linking COVID-19 notification, hospital, 
general practice and death registry data.
The ATHENA COVID-19 Study has two parts 
(see Methods section for detail). Part 1 links 
Queensland COVID-19 notification, hospital 
and death registry data and does not require 
informed consent (access was granted under 
Section 282 of the Public Health Act 2005). 
Part 2 links Queensland COVID-19 notifica-
tion, hospital and death registry data, as well 
as patients’ healthcare information held within 
general practices, and requires patient consent.
The aim of this paper was to report on the estab-
lishment and results for Part 1 of the ATHENA 
COVID-19 Study. We describe hospital-based 
outcomes and deaths among all people diag-
nosed with COVID-19 in Queensland, and 
estimate the strength of association between 
these outcomes and sociodemographic and 
pre-existing health characteristics based on 
routinely-collected data.
Methods
ATHENA is a Queensland-Health-funded 
program involving the integration of primary, 
secondary and other healthcare data sets, using 
informed consent across Queensland. A proof-
of-concept study was completed in June 2019 
involving over 500 patients routinely attending 
two general practices. The principal purpose of 
this proof-of-concept study was twofold. Firstly, 
to assess the proportion of patients consenting 
to have their primary healthcare data extracted 
from their general practice into Queensland 
Health and linked to other data sets for ethically-
approved research. Secondly, to gain permission 
to recontact them in future to discuss clinical 
trial participation. Consent was given by 80% 
of patients to both have their data exported and 
linked, and to be recontacted for trial participa-
tion. The successfully-linked healthcare data 
were tested and found to be highly informative 
for clinical trial design and feasibility testing, 
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while also providing rapid access to large 
numbers of appropriate patients for real-world 
clinical trials. The ATHENA COVID-19 Study 
was opportunistically set up at the start of the 
pandemic, using the same methods to create a 
cohort of all people diagnosed with COVID-19 
in Queensland with linked primary, secondary 
and registry data. These patients would be fol-
lowed from recorded symptom onset date, to 
measure health service use and outcomes and to 
investigate predictors of these outcomes, as well 
as to provide an ongoing resource for future 
clinical trial recruitment.
Data
Part 1 of the ATHENA COVID-19 Study used 
routinely-collected data from the Notifiable 
Conditions System (NoCS) for all people who 
tested positive for the SARS-CoV-2 virus in 
Queensland, linked to data from the Emergency 
Department Collection (EDC), the Queensland 
Health Admitted Patient Data Collection 
(QHAPDC) and Deaths Registrations. The 
NoCS data (1 January – 31 December 2020) 
contained symptom onset date, sociodemo-
graphic characteristics and health outcomes. 
The EDC data (1 January – 31 December 2020) 
included emergency department (ED) arrival 
and departure dates and principal diagnosis. 
The QHAPDC data (1 January 2010 – 30 
January 2021) contained admissions data from 
all public hospitals in Queensland, including 
admission and separation dates, and diagnosis 
codes. In Queensland, people diagnosed with 
COVID-19 have only been admitted to public 
hospitals. Death Registrations data were avail-
able from 1 January 2020 to 17 January 2021. 
Data were linked probabilistically, using name, 
date of birth and address by the Statistical 
Services Branch within Queensland Health, 
applying established protocols.6
Sample
The sample for this study included all peo-
ple in Queensland who tested positive to the 
SARS-CoV-2 virus resulting in COVID-19 
(n = 1,254), identified using NoCS data, from 1 
January 2020 to 31 December 2020 (referred to 
as the Queensland COVID-19 cohort).
Hospital-based outcomes and death
The primary outcomes of interest were: presen-
tation to an ED; inpatient admission to a public 
hospital (which excluded virtual ward at home); 
admission to ICU; use of continuous ventilator 
support; and death. Secondary outcomes were 
time spent: in hospital; in ICU and on ventila-
tion; as well as time between onset date and first 
hospital admission, and between ICU admis-
sion and death.
Presentation to an ED was ascertained from the 
EDC data. Admission to ICU (standard ward 
codes ‘ICU4’, ‘ICU5’ or ‘ICU6’) and continuous 
ventilator support were ascertained from the 
linked QHAPDC data. We included ED presen-
tations and hospital admissions that occurred 
on or up to 6 weeks after symptom onset date, 
or where admission included date of onset.
Sociodemographic and health 
characteristics
Sociodemographic characteristics included age 
(in broad age groups); sex; remoteness (meas-
ured with Accessibility and Remoteness Index 
of Australia [ARIA+]);i socioeconomic status 
(measured using Socio-Economic Indexes 
for Areas, Index of Relative Socio-Economic 
Disadvantage, [SEIFA IRSD]);ii smoking status; 
and health conditions, categorised as shown in 
Table 1.
Smoking status was obtained using information 
from all available QHAPDC records (i.e. prior 
to and after onset date, noting that collection of 
i ARIA+ is a geographical measure of service accessibility based 
on road distances to service centres (based on population 
size), which groups areas into: major cities; inner regional; 
outer regional; remote; and very remote areas.7
ii SEIFA IRSD is an area-based measure of socioeconomic status, 
based on average characteristics of the people living within 
areas containing around 10,000 people.8
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smoking status began on 1 July 2015 and was 
not recorded for virtual ward home admis-
sions). People were categorised as a non-smoker 
if all QHAPDC records indicated that they were 
not a current smoker, or as a current smoker or 
recent smoker if at least one of their QHAPDC 
records indicated that they were a current 
smoker, or otherwise as missing (i.e. virtual 
QHAPDC records).
Comorbid conditions were identified using 
QHAPDC records in the ten years prior to 
onset date, and measured with International 
Statistical Classification of Disease and Related 
Health Problems Version 10 (ICD-10-AM) 
codes. We also used QHAPDC data to measure 
the Elixhauser comorbidity index,9 a weighted 
algorithm based on 30 chronic health conditions 
identified using diagnosis codes, to categorise 
members of the cohort as having 0, 1, or 2+ con-
ditions, or ‘no hospital record prior to infection’. 
Separate categories were chosen to represent ‘no 
hospital record prior to infection’ and ‘0 comor-
bidities’ because an absence of hospital record 
does not necessarily equate to an absence of 
patient comorbidity. Patients may have a history 
of medical disease yet may never have had con-
tact with Queensland Health, the state’s public 
health system, either because: the disease was 
never severe enough to require hospital admis-
sion; the patient may have been admitted to a 
public hospital outside Queensland; the patient 
may have been managed in the private system; or 
because the patient may have been managed in 
primary care.
Analysis
First we described the number and proportions 
of the cohort with each of the primary outcomes, 
as well as the median number of days (with inter-
quartile range, IQR) in hospital and on continu-
ous ventilator support. At the time of analysis, 
days spent in ICU were not available. We also 
cross-checked outcomes reported on the NoCS 
with outcomes derived from the linked data, by 
comparing primary outcomes recorded in the 
hospital and death data with those reported using 
NoCS data. Third, we quantified the association 
between sociodemographic and health charac-
teristics and two outcomes: presentation to an ED 
and inpatient admission to hospital. In this part 
of the analysis, although a person may have more 
than one presentation to an ED or admission to 
hospital (event), the outcome was defined as ever 
compared to never had the outcome. We excluded 
ED presentations and hospital admissions where 
the first day of admission was more than 14 days 
after symptom onset to increase specificity of the 
estimates. We also excluded non-Queensland 
residents (n = 61, defined as having a principal 
address outside Queensland) to maximise the 
proportion captured with hospital admissions 
prior to infection. To assess associations between 
comorbid health conditions and ED and inpa-
tient hospital admissions, we compared those 
with a given health condition to those without 
the condition with linked hospital records; those 
without linked hospital records prior to their 
onset date were included as a separate category. 
Associations were quantified with relative risks 
(RR) and 95% confidence intervals (95% CI), 
estimated using Poisson regression, with adjust-
ment for age, sex and region of residence. Where 
appropriate, we also performed tests for linear 
trend by including ordered categories as continu-
ous terms in models.
Two sets of sensitivity analyses were conducted. 
In the first, we re-estimated associations between 
comorbidities and hospital-based outcomes 
measuring comorbidities using all available 
QHAPDC data, i.e. additionally including admis-
sions occurring after symptom onset date, to 
examine whether associations were similar when 
including diagnoses at the time of COVID-19-
related admissions. In the second, we assumed 
that those without a hospital admission prior to 
their onset date did not have any of the measured 
comorbidities (previously included as a separate 
category), including any of the comorbidities 
measured with the Elixhauser index.
Where possible, we report results stratified by 
sex and broad age group. Missing data were 
included as a separate category. All analyses 
were conducted using Stata version 16.0.
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Total 630 (50.2) 624 (49.8) 1,254
Age group (years)
0–19 38 (6.0) 34 (5.4) 72 (5.7)
20–39 214 (34.0) 271 (43.4) 485 (38.7)
40–59 200 (31.7) 164 (26.3) 364 (29.0)
60–74 138 (21.9) 132 (21.2) 270 (21.5)
75+ 40 (6.3) 23 (3.7) 63 (5.0)
ARIA+b
Major cities 483 (76.7) 490 (78.5) 973 (77.6)
Inner regional 67 (10.6) 66 (10.6) 133 (10.6)
Outer regional / remote / very remote 46 (7.3) 40 (6.4) 86 (6.9)
Non-Queensland resident 34 (5.4) 27 (4.3) 61 (4.9)
SEIFA IRSDc
Most disadvantaged quintile 66 (10.5) 68 (10.9) 134 (10.7)
2nd quintile 70 (11.1) 72 (11.5) 142 (11.3)
3rd quintile 116 (18.4) 100 (16.0) 216 (17.2)
4th quintile 134 (21.3) 150 (24.0) 284 (22.6)
Least disadvantaged quintile 210 (33.3) 206 (33.0) 416 (33.2)
Non-Queensland resident 34 (5.4) 27 (4.3) 61 (4.9)
Smoking status
Non-smoker 316 (50.2) 360 (57.7) 676 (53.9)
Current / recent smoker 34 (5.4) 21 (3.4) 55 (4.4)
Missing 280 (44.4) 243 (38.9) 523 (41.7)
Elixhauser 
comorbidity index
0 283 (44.9) 343 (55) 626 (49.9)
1 56 (8.9) 59 (9.5) 115 (9.2)
2+ 27 (4.3) 28 (4.5) 55 (4.4)
No hospital record prior to infection 264 (41.9) 194 (31.1) 458 (36.5)
Comorbid 
conditionsd
Asthma 6 (1.0) 7 (1.1) 13 (1.0)
Chronic lower respiratory disease 5 (0.8) 8 (1.3) 13 (1.0)
Diabetes 30 (4.8) 23 (3.7) 53 (4.2)
Renal failure 11 (1.7) 8 (1.3) 19 (1.5)
Cancer 40 (6.3) 35 (5.6) 75 (6.0)
Cardiovascular disease 60 (9.5) 37 (5.9) 97 (7.7)
a Sex, age, remoteness and SEIFA IRSD were sourced or derived from the NoCS data. Smoking status and comorbidities were obtained 
from QHAPDC data prior to onset date. SEIFA IRSD was measured in population-based quintiles. Smoking status was only recorded 
from 1 July 2015 and was not recorded for virtual ward home admissions.
b Accessibility and Remoteness Index of Australia.
c Socio-Economic Indexes for Areas, Index of Relative Socio-Economic Disadvantage.
d Asthma (ICD-10-AM: J45); chronic lower respiratory conditions excluding asthma (ICD-10-AM: J40-J47, excluding J45); diabetes 
(ICD-10-AM: E10-E14); renal failure (ICD-10-AM: N17-N19); cancer (ICD-10-AM: C00-C97); and major atherosclerotic/ thromboembolic 
cardiovascular disease (using established methods:10 selected hypertensive diseases I11-I13; ischaemic heart disease I20-I25; pulmo-
nary heart disease and diseases of pulmonary circulation I26-I28; other forms of heart disease I34-36, I42, I44, I46-I51; cerebrovascular 
disease I61-I67, I69; selected diseases of the arteries, arterioles and capillaries I70-I77; phlebitis and thrombophlebitis I80; and selected 
episodic and paroxysmal disorders G45, G46).
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Ethics approval
Ethics approval was granted by the Gold Coast 
Hospital and Health Service Human Research 
Ethics Committee (HREC/2020/QGC/63555) 
and by the Australian National University 
Human Research Ethics Committee (2020/312). 
Informed consent was not required for this 
study and access to de-identified data was 
granted under Section 282 of the Public Health 
Act 2005 by the Director-General’s delegate.
Results
There were 1,254 people with a diagnosis of 
COVID-19 to 31 December 2020. Of these, 
753 (60.0%) were linked to EDC data and most 
(n = 1,178; 93.4%) had a link to a QHAPDC 
record (since January 2010; 30,017 records). Of 
the cohort, there were 288 inpatient hospital 
admissions among 267 (21.3%) patients, while 
796 (63.5%) people had a QHAPDC record in 
the ten years prior to onset date (3,981 records). 
There were six deaths in the linked Death 
Registrations dataset, consistent with the num-
ber of deaths reported by Queensland Health.
Characteristics of all people diagnosed 
with COVID-19 in Queensland
Two thirds of people in the Queensland 
COVID-19 cohort were in the 20–39 and 40–59 
year age groups (38.7% and 29.0% respectively). 
Half of those in the cohort (49.8%) were women 
(Table 1). The majority of people (77.6%) were 
from major cities and a disproportionate num-
ber of cases were from the least disadvantaged 
areas (10.7% of cases were from the most dis-
advantaged quintile, compared to 33.2% from 
the least disadvantaged). Smoking status was 
missing for a large proportion of the cohort 
(523/1,254; 41.7%). Of those for whom smoking 
status could be established, the majority were 
non-smokers (n = 676/731; 92.5%) and a small 
proportion were recorded as current/recent 
smokers (n = 55/731; 7.5%).
For chronic health conditions captured in 
prior public hospital admissions, < 2% of the 
cohort had a previous hospital admission with 
a diagnosis of asthma (1.0%), chronic lower res-
piratory disease (1.0%) or renal failure (1.5%). 
Among the cohort, 4.2% had recorded diabetes; 
6.0% cancer; and 7.7% major cardiovascular 
disease (CVD). The largest fraction of the 
cohort (n= 626/1,254; 49.9%) had none of the 
30 comorbidities measured with the Elixhauser 
comorbidity index; 115 (9.2%) reported one 
comorbid condition; 55 (4.4%) reported two 
or more conditions; and 458 (36.5%) did not 
have a hospital record in the ten years prior to 
infection.
Outcomes for people diagnosed with 
COVID-19 in Queensland
There were 1,182 people in the cohort that had 
an onset date before 1 November 2020 (Table 2). 
The median number of days between symptom 
onset date and first hospitalisation was 4 (IQR: 
2–7 days) and once admitted, median length 
of stay was 11 days (IQR: 8–16). A greater pro-
portion of the cohort aged ≥ 60 years had an 
inpatient hospital admission compared to those 
< 60 years of age (29.9% compared to 18.1%). 
Seventeen members of the cohort (1.4%) with 
onset before 1 November 2020 were admitted 
to ICU, 14 (1.2%) required ventilation and 6 
(0.5%) died. Small numbers experiencing these 
outcomes precluded any further analyses.
The NoCS data recorded that 337 patients (29%) 
were hospitalised, 752 (64%) were not hospital-
ised and hospitalisation status was not recorded 
for 93 cases (8%). By comparison, the QHAPDC 
stated that 250 (21%) patients required inpatient 
hospital admission, an additional 714 (60%) 
were home-based admissions, and 218 (18%) 
had no hospital record (Appendix A, Table 
A.1). The NoCS data recorded that 16 patients 
were admitted to ICU, and that 12 required 
ventilation, which was lower than the numbers 
recorded in the QHAPDC data (Appendix 
A, Tables A.2 and A.3). A large proportion of 
NoCS data pertaining to patient hospitalisation, 
ventilation, admission to ICU and death was 
not recorded (Appendix A, Tables A.1 to A.4).
Over half of the cohort with onset date prior to 
1 November 2020 (57.6%; 681/1,182) presented 
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Table 2: Health outcomes for confirmed COVID-19 cases in Queensland (with onset before 
1 November 2020),a through the Notifiable Conditions Systems (NoCS) data
Maleb Femaleb Total
Total
Presented to emergency department, n (%) 329 (56.0) 352 (59.2) 681 (57.6)
• Inpatient hospital admission, n (%) 135 (23.0) 115 (19.3) 250 (21.2)
• Length of stay (days), median (IQR) 12 (8–17) 11 (7–15) 11 (8–16)
 ◦ Days between onset and hospitalisation, median (IQR) 4 (2–7) 5 (3–8) 4 (2–7)
• Admitted to ICU, n (%) n/a n/a 17 (1.4)
 ◦ Days between onset and ICU, median (IQR) n/a n/a 8 (6–10)
• Required ventilation, n (%) n/a n/a 14 (1.2)
• Days ventilated, median (IQR) n/a n/a 21 (11–35)
• Died, n (%) n/a n/a 6 (0.5)
 ◦ Days between onset and death, median (IQR) n/a n/a 11 (10–24)
Aged 0–59 
years
Presented to emergency department, n (%) 220 (53.4) 258 (58.2) 478 (55.9)
Inpatient hospital admission, n (%) 79 (19.2) 76 (17.2) 155 (18.1)
Aged 60+ 
years
Presented to emergency department, n (%) 109 (62.3) 94 (61.8) 203 (62.1)
Inpatient hospital admission, n (%) 56 (32.0) 39 (25.7) 95 (29.1)
a Estimates are based on cohort members with an onset date prior to 1 November 2020 (n=1,182). Emergency department admissions 
are measured with EDC data; hospital admissions, ICU and continuous ventilator support are measured with the QHAPDC, deaths 
are ascertained with the Death Registrations data. Inpatient hospital records exclude home-based admissions. Hospital data is yet to 
be finalised and these results should be considered preliminary. At the time of writing, data relating to length of stay in ICU was not 
available. Length of stay has been estimated excluding the 13 (7.1%) patients admitted and discharged on the same day.
b n/a indicates that the result has been suppressed because of cell size < 5.
to an ED in the six-week follow-up period. 
The majority (n = 619/681; 90.9%) presented 
within two weeks of their symptom onset date. 
Proportions presenting did not vary substan-
tially by broad age group (55.9% of those aged 
0–59 years, compared to 62.1% of those aged 
60+ years). Among those presenting to an ED, 
the most common primary diagnoses were 
COVID-19 (ICD-10: U07.1) and diagnoses 
related to viral and respiratory infections (Table 
3). The ten most common diagnoses accounted 
for 89.2% of all principal diagnoses among 
those presenting to ED. Diagnoses were materi-
ally unchanged when restricted to presentations 
occurring within two weeks of the recorded 
symptom onset date (see Appendix A, Table A.5).
A total of 250/1,182 people (21.2%) in the 
COVID-19 cohort with onset before 1 November 
2020 were admitted to hospital as an inpatient; 
the majority of admissions (n = 236/250; 94.4%) 
occurred within two weeks of recorded symptom 
onset date. Among those admitted to hospital, 
the most common diagnoses were COVID-19, 
coronavirus, isolation, and symptoms associ-
ated with COVID-19, including cough, fever 
and headache (Table 4). However, the top ten 
most common diagnoses accounted for less 
than half of all diagnoses (47.9%) among this 
patient cohort. Diagnoses were not materially 
different when restricted to admissions occur-
ring within two weeks of recorded symptom 
onset date (Appendix A, Table A.6).
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Table 3: Top 10 principal diagnosis codes among COVID-19 patients presenting to an emergency 
department in Queenslanda
Rank ICD-10-AM code Definition of ICD-10-AM code n %
Cumulative
%
1 U07.1 Emergency use of U07.1 (COVID-19) 288 28.8 28.8
2 B34.9 Viral infection, unspecified 271 27.1 55.9
3 Z11.5 Special screening examination for other viral diseases 225 22.5 78.4
4 J06.9 Acute upper respiratory infection, unspecified 36 3.6 82.0
5 B34.2 Coronavirus infection, unspecified site 29 2.9 84.9
6 Z09.9 Follow-up examination after unspecified treatment for other conditions 12 1.2 86.1
7 R07.4 Chest pain, unspecified 8 0.8 86.9
8 J22 Unspecified acute lower respiratory infection 8 0.8 87.7
9 J11.1 Influenza with other respiratory manifestations, virus not identified 8 0.8 88.5
10 R50.9 Fever, unspecified 7 0.7 89.2
a Estimates are based on 998 admissions among 681 patients. Outcomes are measured with EDC data.
Factors associated with a presentation to 
an emergency department or admission 
to hospital
There were 1,148 people who were residents 
of Queensland with an onset date before 1 
November 2020. Among these people, there was 
little variation in risks associated with presenta-
tion to an ED in relation to sociodemographic 
characteristics after adjustment for age and 
sex (Table 5), other than that those residing in 
outer regional areas had lower risk of present-
ing to an ED than did those in major cities 
(age-sex-adjusted RR: 0.64; 95% CI: 0.44, 0.92; 
test for trend: p = 0.007). In age-sex-adjusted 
models, there was evidence that those in less-
disadvantaged areas had higher risks of present-
ing to an ED (test for trend, p = 0.014); however, 
this association was no longer evident after 
ARIA+ region classification was considered.
Proportions admitted to hospital increased with 
age (< 20% of those aged 0–39 years to > 34% 
of those aged 75+ years); with being a current/
recent smoker (42.2%) compared to being a 
non-smoker (27.9%); and with having a comor-
bid chronic health condition (26.3–38.5%) 
compared to having no comorbid condition 
(18.8%). There was considerable uncertainty in 
the estimates in the age-sex-adjusted models. 
However, risk of hospital admission increased 
with greater age (test for linear trend: p < 0.001) 
and was elevated among current/recent smok-
ers compared to non-smokers (age-sex-adjusted 
RR:1.62; 95% CI: 1.00, 2.61); those living in 
less-disadvantaged areas had lower risk of being 
admitted to hospital (age-sex-adjusted test for 
trend, p = 0.001) (Model 1, Table 6). There was 
no material difference in these results after 
adjustment for region (Model 2, Table 6).
Sensitivity analyses
When comorbidities were measured using 
hopsitalisation records both before and after 
COVID-19 symptom onset, the proportions 
of cases with each of the comorbid health 
conditions increased slightly (see Appendix 
A, Table A.7). Associations between comor-
bid health conditions and presentation to 
emergency (Appendix A, Table A.8) were sub-
stantially unchanged. Associations between 
comorbid health conditions and inpatient 
hospital admissions did not change materi-
ally, except that those with renal failure had 
higher risk of hospital admission compared 
to those without (age-sex adjusted RR= 1.75; 
95% CI: 1.07, 2.86; Appendix A, Table A.9). 
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Table 4: Top 10 principal diagnosis codes among COVID-19 patients requiring inpatient 
admission to hospital in Queenslanda
Rank ICD-10-AM code Definition of ICD-10-AM code n % Cumulative %
1 U07.1 Emergency use of U07.1 (COVID-19) 257 11.5 11.5
2 Z29.0 Isolation 234 10.5 22.0
3 B97.2 Coronavirus as the cause of disease classified to other chapters 216 9.7 31.7
4 R05 Cough 85 3.8 35.5
5 U82.3b Hypertension 51 2.3 37.8
6 R50.9 Fever, unspecified 50 2.2 40.0
7 Z86.43 Personal history of psychoactive substance abuse, tobacco use disorder 49 2.2 42.2
8 B34.2 Coronavirus infection, unspecified site 45 2.0 44.2
9 J128 Other viral pneumonia 41 1.8 46.1
10 R51 Headache 40 1.8 47.9
a Estimates are based on 380 inpatient admissions among 250 patients. Outcomes are measured with data from the QHAPDC.
b U82.3 Hypertension is a supplementary code, assigned when a condition is present on admission but that does not meet the criteria 
for coding as instructed by the general and specialty coding standards, coding conventions, and coding rules.
Some caution should be applied when interpret-
ing these results, as health conditions measured 
at the time or after onset may be the outcome 
of COVID-19 rather than a pre-existing condi-
tion. Similarly, associations between comorbid 
conditions and outcomes were materially 
unchanged when assuming those without a 
hospital record prior to onset date had none 
of the measured comorbidities (Appendix A, 
Tables A.10 and A.11).
Discussion
By linking administrative data, we described 
the characteristics, hospital-based outcomes 
and deaths for all confirmed COVID-19 cases in 
Queensland, and the utility of using linked data 
for ongoing surveillance purposes as the pan-
demic continues. Over half of people diagnosed 
had at least one ED presentation; one in five 
had an inpatient hospital admission (median 
length of stay 11 days), 1.4% were admitted to 
ICU (majority requiring ventilation) and six 
died. Increasing age and being a smoker were 
associated with higher risk of admission, while 
those in less-disadvantaged areas had lower risk 
of admission. There was some evidence that 
people with chronic health conditions had an 
elevated risk of being admitted; however, small 
numbers limited the precision of our estimates.
Our finding that presentations to an ED were rel-
atively common is consistent with Queensland 
policies regarding testing location during the 
pandemic. The majority of those diagnosed 
with COVID-19 in Queensland acquired the 
virus overseas and were likely in quarantine 
when symptoms became apparent.11 Emergency 
Departments were the first point of contact for 
these people. Even those not in quarantine were 
discouraged from entering GP clinics if they 
reported any COVID-19 related symptoms, and 
were instead referred to their nearest ED. This 
policy remained in place even after State and 
Commonwealth Governments established fever 
clinics which would have reduced the number 
of patients presenting to an ED. The only char-
acteristic we examined that was associated with 
lower risk of presenting to an ED was living in 
an outer regional area, likely reflecting reduced 
access to an ED.
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Table 5: Proportions and relative risks for emergency department presentation within two weeks 
of recorded symptom onset among Queensland residents with confirmed COVID-19,a in relation 




Model 1 RR 
(95% CI)





0–19 24/63 (38.1) 0.73 (0.48, 1.11) 0.72 (0.47, 1.09)
20–39 226/432 (52.3) 1.00 1.00
40–59 172/328 (52.4) 1.00 (0.82, 1.22) 1.01 (0.82, 1.23)
60–74 148/264 (56.1) 1.07 (0.87, 1.32) 1.08 (0.88, 1.33)
75+ 37/61 (60.7) 1.16 (0.82, 1.65) 1.18 (0.83, 1.68)
Sexb
Male 300/566 (53.0) 1.00 1.00
Female 307/582 (52.7) 1.00 (0.85, 1.18) 1.00 (0.85, 1.17)
ARIA+c
Major cities 516/935 (55.2) 1.00 –
Inner regional 60/127 (47.2) 0.83 (0.64, 1.09) –
Outer regional / remote / very remote 30/85 (35.3) 0.64 (0.44, 0.92)d –
SEIFA IRSDe
Most disadvantaged quintile 56/127 (44.1) 1.00 1.00
2nd quintile 62/141 (44) 0.97 (0.67, 1.39) 1.03 (0.71, 1.48)
3rd quintile 105/199 (52.8) 1.19 (0.86, 1.65) 1.19 (0.85, 1.67)
4th quintile 152/277 (54.9) 1.25 (0.92, 1.69) 1.20 (0.86, 1.66)
Least disadvantaged quintile 231/403 (57.3) 1.32 (0.98, 1.77)f 1.25 (0.92, 1.71)
Smoking 
status
Non-smoker 357/613 (58.2) 1.00 1.00
Current / recent smoker 26/45 (57.8) 1.00 (0.67, 1.50) 1.00 (0.67, 1.49)




0 326/612 (53.3) 1.00 1.00
1 64/113 (56.6) 1.03 (0.78, 1.36) 1.04 (0.79, 1.36)
2+ 28/54 (51.9) 0.93 (0.63, 1.38) 0.95 (0.64, 1.41)
No hospital record prior to infection 189/369 (51.2) 0.99 (0.82, 1.19) 0.98 (0.82, 1.18)
Comorbid 
conditionsg
Asthma 8/12 (66.7) 1.28 (0.64, 2.59) 1.24 (0.61, 2.51)
Chronic lower respiratory disease 9/13 (69.2) 1.22 (0.63, 2.40) 1.21 (0.61, 2.36)
Diabetes 34/52 (65.4) 1.18 (0.82, 1.70) 1.22 (0.84, 1.76)
Renal failure 11/19 (57.9) 1.03 (0.56, 1.89) 1.03 (0.56, 1.89)
Cancer 37/73 (50.7) 0.88 (0.62, 1.25) 0.88 (0.62, 1.25)
Cardiovascular disease 54/97 (55.7) 0.98 (0.73, 1.33) 1.00 (0.74, 1.36)
a Estimates are based on 1,148 people who were residents of Queensland with an onset date before 1 November 2020 and 607 presenta-
tions to emergency departments, measured with EDC data. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex and 
remoteness, measured with ARIA+. Age, sex, remoteness and SEIFA IRSD are measured with or derived from NoCS data. Smoking status 
and comorbidities are measured with QHAPDC prior to onset date. SEIFA IRSD is measured in population-based quintiles.
b Where age is the primary exposure variable, Model 1 is adjusted only for sex. Where sex is the primary exposure variable, Model 1 is 
adjusted for only age. EDC data is yet to be finalised and results should be considered preliminary.
c Accessibility and Remoteness Index of Australia.
d Indicates that the test for linear trend was significant, p < 0.01.
e Socio-Economic Indexes for Areas, Index of Relative Socio-Economic Disadvantage.
f Indicates that the test for linear trend was significant, p < 0.05.
g Risks associated with comorbid conditions are estimated for each condition separately, using those with a hospital record but without 
the condition as the reference category.
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Table 6: Proportions and relative risks for an inpatient admission to hospital within two 





Model 1 RR 
(95% CI)





0–19 11/ 63 (17.5) 1.13 (0.60, 2.14) 1.18 (0.62, 2.23)
20–39 66/ 432 (15.3) 1.00 1.00
40–59 61/ 328 (18.6) 1.19 (0.84, 1.69) 1.19 (0.84, 1.69)
60–74 68/ 264 (25.8) 1.66 (1.19, 2.34) 1.68 (1.19, 2.36)
75+ 21/ 61 (34.4) 2.17 (1.32, 3.56)c 2.20 (1.34, 3.63)c
Sexb
Male 124/566 (21.9) 1.00 1.00
Female 103/582 (17.7) 0.85 (0.65, 1.10) 0.86 (0.66, 1.11)
ARIA+d
Major cities 171/935 (18.3) 1.00 –
Inner regional 28/127 (22) 1.08 (0.72, 1.62) –
Outer regional / remote / very remote 28/85 (32.9) 1.83 (1.22, 2.73)e –
SEIFA IRSDf
Most disadvantaged quintile 45/127 (35.4) 1.00 1.00
2nd quintile 38/141 (27) 0.74 (0.48, 1.15) 0.70 (0.45, 1.08)
3rd quintile 46/199 (23.1) 0.67 (0.45, 1.02) 0.60 (0.39, 0.92)
4th quintile 56/277 (20.2) 0.60 (0.40, 0.89) 0.55 (0.36, 0.83)
Least disadvantaged quintile 42/403 (10.4) 0.32 (0.21, 0.48)c 0.30 (0.19, 0.46)c
Smoking 
status
Non-smoker 171/613 (27.9) 1.00 1.00
Current / recent smoker 19/45 (42.2) 1.62 (1.00, 2.61) 1.61 (1.00, 2.61)




0 115/612 (18.8) 1.00 1.00
1 30/113 (26.5) 1.22 (0.81, 1.84) 1.21 (0.80, 1.82)
2+ 15/54 (27.8) 1.21 (0.70, 2.10) 1.20 (0.69, 2.08)
No hospital record prior to infection 67/369 (18.2) 1.03 (0.76, 1.41) 1.03 (0.76, 1.41)
Comorbid 
conditionsg
Asthma < 5/12 (< 42.0) 1.15 (0.37, 3.63) 1.22 (0.39, 3.84)
Chronic lower respiratory disease 5/13 (38.5) 1.47 (0.59, 3.66) 1.54 (0.62, 3.85)
Diabetes 16/52 (30.8) 1.18 (0.69, 2.01) 1.23 (0.66, 1.94)
Renal failure 5/19 (26.3) 1.00 (0.41, 2.46) 1.04 (0.42, 2.57)
Cancer 20/73 (27.4) 1.07 (0.66, 1.75) 1.08 (0.66, 1.77)
Cardiovascular disease 28/97 (28.9) 1.13 (0.74, 1.75) 1.12 (0.73, 1.73)
a Estimates are based on 1,148 people who were residents of Queensland with an onset date before 1 November 2020 and 227 inpatient 
hospital admissions, measured with QHAPDC data. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex and remote-
ness, measured with ARIA+. Age, sex, remoteness and SEIFA IRSD are measured with or derived from NoCS data. Smoking status and 
comorbidities are measured with hospital data prior to onset date. SEIFA IRSD is measured in population-based quintiles.
b Where age is the primary exposure variable, Model 1 is adjusted only for sex. Where sex is the primary exposure variable, Model 1 is 
adjusted for only age. QHAPDC data is yet to be finalised and results should be considered preliminary.
c Indicates that the test for linear trend was significant, p < 0.001.
d Accessibility and Remoteness Index of Australia.
e Indicates that the test for linear trend was significant, p < 0.01.
f Socio-Economic Indexes for Areas, Index of Relative Socio-Economic Disadvantage.
g Risks associated with comorbid conditions are estimated for each condition separately, using those with a hospital record but without 
the condition as the reference category.
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Proportions of people diagnosed with 
COVID-19 experiencing adverse outcomes are 
likely to be dependent on a number of region-
specific factors, including population profile, 
health system factors and the public health 
actions taken by individuals and Government. 
Furthermore, international comparisons 
with people diagnosed with COVID-19 in 
Queensland are difficult, given that most 
previous research examines outcomes among 
ED presentations and hospitalised COVID-19 
patients and/or expresses outcomes as rates 
(rather than proportions).12,13
The associations between person character-
istics and inpatient hospital admissions in the 
Queensland COVID-19 cohort were consist-
ent with what is already known about adverse 
outcomes in people diagnosed with COVID-19. 
Previous research has found that increasing 
age, being a smoker and area-level deprivation 
are associated with adverse outcomes in people 
diagnosed with COVID-19 compared to other 
members of the population, as are chronic 
health conditions such as respiratory disease 
(excluding asthma), cardiovascular disease, 
diabetes, recent cancer and reduced kidney 
function.14,15
This project demonstrates the value of data 
linkage across health services to monitor 
outcomes and contribute to the international 
evidence on COVID-19. NoCS data, whilst 
valuable, is limited by incomplete data records, 
by the impracticability of collecting extra infor-
mation such as comorbidities, and by the time 
needed for long-term follow-up. Queensland 
Health already has a wide array of established 
data sets which contain valuable and additional 
health care information. Linking NoCS data 
to additional data sources – hopsitalisations, 
emergency department and death data – has 
enabled additional and complementary data 
for people with COVID-19 (including more 
complete outcome data), ultimately increasing 
the value of the NoCS data collected from case 
report forms. Furthermore, it has allowed for 
ascertainment of hospital-based and death out-
comes for all people diagnosed with COVID-19, 
which has been limited in many international 
settings to only those admitted to hospital. 
Having established the resource, the ATHENA 
COVID-19 Study can now also be used a plat-
form for monitoring longer-term outcomes. 
In order to both strengthen and increase the 
utility of existing notifiable disease surveillance 
systems against future pandemics, it would 
seem prudent to routinely establish the linkage 
capabilities between these different databases.
Nonetheless, our findings, particularly those 
regarding associations between pre-existing 
conditions and hospital outcomes, should be 
interpreted with data limitations in mind. 
Hospital data were limited to Queensland 
public hospitals. There were no Queensland 
COVID-19-related admissions to private hospi-
tals in Queensland or to hospitals outside the 
state, and hence, ascertainment of hospital out-
comes is likely complete. However, our measure 
of comorbidities based on hospital data (in the 
ten years prior to COVID-19 diagnosis) is likely 
incomplete, given some cohort members may 
have been admitted to private hospital or to a hos-
pital outside Queensland in the relevant period. 
There may also be missing data due to linkage 
error. Consequently, prevalence of these condi-
tions will be underestimated, which may or may 
not have affected RR estimates of the associa-
tions between chronic conditions and inpatient 
hospital admission. The sociodemographic and 
health characteristics included were limited to 
the data that were available; other information, 
including more detail on health conditions and 
information on medications, would have been 
useful. Discrepancies between the NoCS and 
QHAPDC data most likely reflect a combination 
of non-recorded data (NoCS) and no hospital 
record available (QHAPDC). That 93%, rather 
than 100%, of COVID-19 patients had data 
linked to QHAPDC is likely due to the delay in 
virtual wards being set up. During this period, 
those patients who were asymptomatic or 
mildly ill would not have required admission to 
hospital and therefore would not have evidence 
of admitted data. Finally, reflecting the success 
that Queensland showed in curbing the pan-
demic, there were small numbers of COVID-19 
cases in this study. This resulted in considerable 
uncertainty in estimates of association between 
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characteristics and outcomes, limiting our abil-
ity to examine factors predicting hospital-based 
outcomes.
The ATHENA COVID-19 Study is now an 
established resource. While Australia’s success 
managing the pandemic has ensured cases have 
remained low since the peak of the pandemic in 
Queensland in late March 2020, the ATHENA 
COVID-19 Study can be used for monitoring of 
COVID-19 outcomes should there be another 
wave or increased community transmission, 
as well as longer-term follow-up. Furthermore, 
the data could be aggregated with similar data 
from other Australian states and territories to 
increase their analytical power.
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Appendix A: Supplementary tables
Table A.1: Number of cases with onset date before 1 November 2020 reported as being 
hospitalised in the Notifiable Conditions System data (NoCS) and the linked data from 
Queensland Health Admitted Patient Data Collection (QHAPDC)
QHAPDC data
No hospital record Home-based admission Inpatient hospital admission Total
NoCS 
data
Not hospitalised 194 500 58 752
Hospitalised 14 146 177 337
Not recorded 10 68 15 93
Total 218 714 250 1,182
Table A.2: Number of cases with onset date before 1 November 2020 reported as requiring 











Not ventilated 40 217 < 5 XXXX
Required ventilation < 5 < 5 < 5 12
Not recorded 177 733 < 5 XXXX
Totala XXXX XXXX 14 1,182
Table A.3: Number of cases with onset date before 1 November 2020 reported as being admitted 






Admitted to ICU Totala
NoCS 
data
Not admitted to ICU 156 649 < 5 XXXX
Admitted to ICU < 5 XXXX < 5 16
Not recorded 59 298 < 5 XXXX
Totala XXXX XXXX 17 1,182
Table A.4: Number of cases with onset date before 1 November 2020 reported as having died in 
the NoCS data and the linked Death Registrations data
Death Registrations data
No record Died Totala
NoCS 
data
Not recorded as having died 959 < 5 XXXX
Recorded as having died < 5 < 5 6
Not recorded XXXX < 5 XXXX
Totala 1,176 6 1,182
a 'XXXX' indicates that the number has been suppressed.
a 'XXXX' indicates that the number has been suppressed.
a 'XXXX' indicates that the number has been suppressed.
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Table A.5: Top 10 principal diagnosis codes among COVID-19 patients presenting to an 




Definition of ICD-10-AM code n % Cumulative %
1 B34.9 Viral infection, unspecified 236 31.9 31.9
2 U07.1 Emergency use of U07.1 (COVID-19) 191 25.8 57.7
3 Z11.5 Special screening examination for other viral diseases 167 22.6 80.3
4 J06.9 Acute upper respiratory infection, unspecified 31 4.2 84.5
5 B34.2 Coronavirus infection, unspecified site 28 3.8 88.2
6 J18.9 Pneumonia, unspecified 7 0.9 89.2
7 J11.1 Influenza with other respiratory manifestations, virus not identified 7 0.9 90.1
8 R50.9 Fever, unspecified 7 0.9 91.1
9 R07.4 Chest pain, unspecified 5 0.7 91.8
10 J22 Unspecified acute lower respiratory infection 5 0.7 92.4
a Estimates are based on 740 presentations among 622 patients. Outcomes are measured with data from the QHAPDC.
Table A.6: Top 10 principal diagnosis codes among COVID-19 patients within two weeks of 




Definition of ICD-10-AM code n % Cumulative %
1 U07.1 Emergency use of U07.1 (COVID-19) 240 11.7 11.7
2 Z29.0 Isolation 219 10.7 22.4
3 B97.2 Coronavirus 200 9.7 32.1
4 R05 Cough 77 3.8 35.8
5 U82.3b Hypertension 45 2.2 38.0
6 R50.9 Fever 45 2.2 40.2
7 B34.2 Coronavirus infection unspecific site 43 2.1 42.3
8 Z86.43 Personal history of psychoactive substance abuse, tobacco use disorder 43 2.1 44.4
9 J128 Other viral pneumonia 40 1.9 46.4
10 R51 Headache 35 1.7 48.1
a Estimates are based on 1065 inpatient admissions among 938 patients. Outcomes are measured with data from the QHAPDC.
b U82.3 Hypertension is a supplementary code, assigned when a condition is present on admission but that does not meet the criteria 
for coding as instructed by the general and specialty coding standards, coding conventions, and coding rules.
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Table A.7: Proportions of confirmed COVID-19 cases with comorbid chronic health conditions,a 








Asthma 16 (2.5) 22 (3.5) 38 (3.0)
Chronic lower respiratory disease 10 (1.6) 9 (1.4) 19 (1.5)
Diabetes 43 (6.8) 30 (4.8) 73 (5.8)
Renal failure 28 (4.4) 12 (1.9) 40 (3.2)
Cancer 40 (6.3) 35 (5.6) 75 (6.0)
Cardiovascular Disease (CVD) 73 (11.6) 40 (6.4) 113 (9.0)
a Estimates are based on all 1,254 cohort members.
Table A.8: Crude and age-sex-adjusted risks for emergency department presentation among 
Queensland residents with confirmed COVID-19 in relation to comorbid conditions,a including 
QHAPDC records post COVID-19 onset
Comorbidity Events/persons (%) Age-sex-adjusted RR (95% CI)
Asthma 26/36 (72.2) 1.13 (0.76, 1.68)
Chronic lower respiratory disease 15/18 (83.3) 1.25 (0.73, 2.14)
Diabetes 45/68 (66.2) 1.00 (0.72, 1.37)
Renal failure 27/39 (69.2) 1.05 (0.70, 1.56)
Cancer 44/73 (60.3) 0.88 (0.63, 1.22)
Cardiovascular Disease (CVD) 72/112 (64.3) 0.97 (0.74, 1.28)
a Estimates are based on 1,148 cohort members who were Queensland residents and had an onset date before 1 November 2020.
Comorbidity Events/persons (%) Age-sex-adjusted RR (95% CI)
Asthma 11/36 (30.6) 1.32 (0.71, 2.45)
Chronic lower respiratory disease 9/18 (50.0) 1.65 (0.81, 3.36)
Diabetes 22/68 (32.4) 1.10 (0.69, 1.76)
Renal failure 20/39 (51.3) 1.75 (1.07, 2.86)
Cancer 20/73 (27.4) 0.91 (0.56, 1.48)
Cardiovascular Disease (CVD) 40/112 (35.7) 1.30 (0.88, 1.92)
a Estimates are based on 1,148 cohort members who were Queensland residents and had an onset date before 1 November 2020.
Table A.9: Crude and age-sex-adjusted risks for inpatient hospital admission within 2 weeks 
of symptoms onset among Queensland residents with confirmed COVID-19 in relation to 
comorbid conditions,a including QHPADC records post COVID-19 onset
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Table A.10: Crude and age-sex-adjusted risks for emergency department presentation among 
Queensland residents with confirmed COVID-19 in relation to comorbid conditions,a assuming 
patients with no QHAPDC records prior to onset had none of the measured comorbidities
Comorbidity Events/persons (%) Age-sex-adjusted RR (95% CI)
Asthma 9/12 (75.0) 1.31 (0.68, 2.53)
Chronic lower respiratory disease 11/13 (84.6) 1.36 (0.74, 2.50)
Diabetes 37/52 (71.2) 1.17 (0.83, 1.67)
Renal failure 12/19 (63.2) 1.03 (0.58, 1.84)
Cancer 44/73 (60.3) 0.97 (0.71, 1.34)
Cardiovascular Disease (CVD) 59/97 (60.8) 0.99 (0.75, 1.32)
a Estimates are based on 1,148 cohort members who were Queensland residents and had an onset date before 1 November 2020.
Table A.11: Crude and age-sex-adjusted risks for inpatient hospital admission within two weeks 
of symptoms onset among Queensland residents with confirmed COVID-19 in relation to 
comorbid conditions,a assuming patients with no QHAPDC records prior to onset had none of 
the measured comorbidities
Comorbidity Events/persons (%) Age-sex-adjusted RR (95% CI)
Asthma < 5/12 (<42) 1.15 (0.37, 3.63)
Chronic lower respiratory disease 5/13 (38.5) 1.48 (0.60, 3.66)
Diabetes 16/52 (30.8) 1.18 (0.69, 2.01)
Renal failure 5/19 (26.3) 1.00 (0.41, 2.46)
Cancer 20/73 (27.4) 1.07 (0.66, 1.74)
Cardiovascular Disease (CVD) 28/97 (28.9) 1.13 (0.74, 1.74)
a Estimates are based on 1,148 cohort members who were Queensland residents and had an onset date before 1 November 2020.
